Exicure Inc

NASDAQ:XCURUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Exicure, Inc. is an early stage biotechnology company. It is developing nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It is engaged in the development of its preclinical program targeting SCN9A for neuropathic pain; to develop SNA-based treatments in neuroscience targeting Huntingtons disease and Angelman syndrome; to develop Spherical Nucleic Acid (SNA)-based treatments for hair loss disorders; as well as the continued research and development of other therapeutic product candidates. SCN9A is its lead program candidate for the treatment of chronic pain. Cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9), agonist designed for immuno-oncology applications utilizing its SNA technology. Its therapeutic discovery and development efforts are supported by its SNA technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid molecules that are radially arranged in three dimensions.

Contact Information

Headquarters

2430 N. HALSTED ST.CHICAGO, IL, United States 60614

Phone

847-673-1700

Fax

847-556-6411

Executives

Chairman of the Board

Seung Soo Shin

President, Chief Executive Officer, Director

Matthias Schroff

Chief Financial Officer

Elias Papadimas

Chief Human Resource and Compliance Officer

Sarah Longoria

Director

Changil Ahn